Alnylam Pharmaceuticals, Inc. $ALNY Shares Bought by Panagora Asset Management Inc.

Panagora Asset Management Inc. increased its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 74.5% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 96,804 shares of the biopharmaceutical company's stock after buying an additional 41,340 shares during the quarter. Panagora Asset Management Inc. owned about 0.07% of Alnylam Pharmaceuticals worth $26,139,000 at the end of the most recent reporting period.Alnylam Stock Soars 65%: Find Out What’s Behind the GainsSeveral other hedge funds have also bought and sold shares of the stock. Orbis Allan Gray Ltd boosted its position in Alnylam Pharmaceuticals by 11.0% in the 1st quarter. Orbis Allan Gray Ltd now owns 1,634,923 shares of the biopharmaceutical company's stock worth $441,462,000 after purchasing an additional 162,121 shares in the last quarter. Vident Advisory LLC boosted its position in Alnylam Pharmaceuticals by 101.0% in the 1st quarter. Vident Advisory LLC now owns 2,667 shares of the biopharmaceutical company's stock worth $720,000 after purchasing an additional 1,340 shares in the last quarter. Kodai Capital Management LP purchased a new stake in Alnylam Pharmaceuticals in the 1st quarter worth approximately $5,713,000. Driehaus Capital Management LLC boosted its position in Alnylam Pharmaceuticals by 70.6% in the 1st quarter. Driehaus Capital Management LLC now owns 57,128 shares of the biopharmaceutical company's stock worth $15,426,000 after purchasing an additional 23,648 shares in the last quarter. Finally, Iron Triangle Partners LP purchased a new stake in Alnylam Pharmaceuticals in the 1st quarter worth approximately $17,662,000. Hedge funds and other institutional investors own 92.97% of the company's stock. Insiders Place Their BetsIn other Alnylam Pharmaceuticals news, EVP Pushkal Garg sold 1,455 shares of the firm's stock in a transaction on Tuesday, August 19th. The stock was sold at an average price of $458.41, for a total value of $666,986.55. Following the completion of the sale, the executive vice president directly owned 20,221 shares of the company's stock, valued at $9,269,508.61. This trade represents a 6.71% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Jeffrey V. Poulton sold 2,274 shares of the firm's stock in a transaction on Monday, August 18th. The stock was sold at an average price of $453.27, for a total value of $1,030,735.98. Following the completion of the sale, the executive vice president directly owned 50,121 shares of the company's stock, valued at $22,718,345.67. This trade represents a 4.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 76,891 shares of company stock worth $31,456,338. 1.50% of the stock is currently owned by company insiders. Analysts Set New Price Targets3 biotech powerhouses poised to thrive amid sector reboundSeveral equities research analysts have commented on ALNY shares. Raymond James Financial started coverage on Alnylam Pharmaceuticals in a research report on Wednesday, July 30th. They issued an "outperform" rating and a $370.00 price objective on the stock. Morgan Stanley increased their target price on Alnylam Pharmaceuticals from $312.00 to $405.00 and gave the company an "equal weight" rating in a research report on Friday, August 1st. Oppenheimer upgraded Alnylam Pharmaceuticals from a "market perform" rating to an "outperform" rating and set a $490.00 target price on the stock in a research report on Monday, August 4th. Scotiabank increased their target price on Alnylam Pharmaceuticals from $342.00 to $450.00 and gave the company a "sector outperform" rating in a research report on Friday, August 1st. Finally, JPMorgan Chase & Co. increased their target price on Alnylam Pharmaceuticals from $348.00 to $475.00 and gave the company an "overweight" rating in a research report on Wednesday, August 6th. Twenty-two investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $405.33.Get Our Latest Research Report on Alnylam PharmaceuticalsAlnylam Pharmaceuticals Trading Down 1.3%Argenx's 28% Surge & Promising Product Propel Investor ConfidenceShares of ALNY stock opened at $446.51 on Friday. The stock's fifty day moving average is $374.57 and its two-hundred day moving average is $302.99. The company has a debt-to-equity ratio of 4.10, a quick ratio of 2.75 and a current ratio of 2.80. The firm has a market capitalization of $58.53 billion, a P/E ratio of -180.77 and a beta of 0.25. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $205.87 and a fifty-two week high of $469.81. Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, beating analysts' consensus estimates of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The company had revenue of $773.69 million for the quarter, compared to analyst estimates of $633.54 million. During the same quarter last year, the firm posted ($0.13) EPS. The firm's revenue for the quarter was up 17.3% on a year-over-year basis. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year. Alnylam Pharmaceuticals Company Profile (Free Report)Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.Recommended StoriesFive stocks we like better than Alnylam PharmaceuticalsWhy Are Stock Sectors Important to Successful Investing?DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy?What is Short Interest? How to Use ItEngines to AI: Cummins’ Surprising Growth DriverHow to Use Stock Screeners to Find StocksSmaller Industrials Names Seeing Surging Growth: Here's WhyWant to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report).This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Alnylam Pharmaceuticals Right Now?Before you consider Alnylam Pharmaceuticals, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alnylam Pharmaceuticals wasn't on the list.While Alnylam Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here